ONCODESIGN Logo

ONCODESIGN

Developing precision oncology solutions for resistant and metastatic cancers.

ALONC | PA

Overview

Corporate Details

ISIN(s):
FR0011766229
LEI:
9695004HPDBVG72O8851
Country:
France
Address:
20 RUE JEAN MAZEN, 21000 DIJON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Oncodesign Precision Medicine (OPM) is a biotechnology company dedicated to developing innovative therapeutic and diagnostic solutions. The company's core mission is to address therapeutic resistance and metastasis in cancer through a precision medicine approach. Utilizing a patient-centric, translational model, OPM focuses on discovering and advancing treatments for patients with resistant and metastatic cancers. The company collaborates with clinicians, service providers, and experts to guide its research and development investments towards meeting significant unmet medical needs in oncology.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-12-13 14:25
Delisting Announcement
Communiqués publiés en période d'offre publique d'acquisition / OPA Autres comm…
French 150.7 KB
2022-12-13 11:17
Major Shareholding Notification
Franchissement de seuils
French 209.0 KB
2022-11-24 08:00
M&A Activity
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 145.1 KB
2022-11-23 17:37
Prospectus
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 724.9 KB
2022-11-23 17:36
M&A Activity
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 2.3 MB
2022-11-08 16:38
M&A Activity
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 2.2 MB
2022-11-08 15:54
Delisting Announcement
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 231.6 KB
2022-11-02 17:28
Prospectus
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 1.0 MB
2022-11-02 17:25
Prospectus
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 506.0 KB
2022-10-26 11:17
Major Shareholding Notification
Franchissement de seuil
French 198.3 KB
2022-10-26 11:16
Major Shareholding Notification
Franchissement de seuils
French 206.0 KB
2022-10-19 08:00
M&A Activity
Inside Information / Operations of the issuer (acquisitions, sales...)
English 340.5 KB
2022-10-19 08:00
M&A Activity
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
French 390.8 KB
2022-10-04 18:00
Delisting Announcement
Inside Information / Other news releases
English 268.6 KB
2022-10-04 18:00
Delisting Announcement
Informations privilégiées / Autres communiqués
French 273.9 KB

Automate Your Workflow. Get a real-time feed of all ONCODESIGN filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ONCODESIGN

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ONCODESIGN via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Gencurix Inc. Logo
Develops molecular diagnostic tests for cancer detection, prognosis, and treatment selection.
South Korea
229000
GENELUX Corp Logo
Developing oncolytic viral immunotherapies for difficult-to-treat cancers using a vaccinia virus.
United States of America
GNLX
GENEMATRIX INC. Logo
Develops multiplex PCR diagnostics and new drugs for infectious diseases like HPV and tuberculosis.
South Korea
109820
Genenta Science S.p.A. Logo
Develops cell & gene therapies using engineered stem cells to treat solid tumors.
United States of America
GNTA
GeneOne Life Science, Inc. Logo
Develops nucleic acid vaccines & therapies for infectious diseases, cancer & autoimmune disorders.
South Korea
011000
Generation Bio Co. Logo
Developing siRNA genetic medicines via targeted nanoparticles for autoimmune diseases.
United States of America
GBIO
Genetic Analysis AS Logo
Develops microbiome diagnostics to detect gut dysbiosis for clinical and pharma partners.
Norway
GEAN
GENFIT Logo
Biopharma developing therapies & diagnostics for rare, life-threatening liver diseases.
France
GNFT
Genfit S.A. Logo
Biopharma developing therapeutics and diagnostics for rare and life-threatening liver diseases.
United States of America
GNFT
GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Logo
Develops and manufactures pharmaceuticals for rare diseases and unmet health needs globally.
Türkiye
GENIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.